Last updated: April 7, 2026
What is CHOLEBRINE?
CHOLEBRINE is a gastrointestinal drug primarily used to treat biliary colic, gallstones, and related biliary disorders. It is typically marketed for its cholagogic properties, aiding bile flow and stone dissolution. The drug’s composition usually involves bile acids or bile salts, which are naturally occurring substances that facilitate the digestion and dissolution of cholesterol-based stones.
Market Overview
The global market for biliary disorder treatments, including drugs like CHOLEBRINE, is driven by the rising incidence of gallstone disease. The International Study of Gallbladder and Biliary Tract Disease estimates that biliary diseases affect approximately 10-15% of adults worldwide.
Market Size and Growth
| Year |
Estimated Market Size (USD billion) |
CAGR (2022-2027) |
| 2022 |
2.1 |
4.2% |
| 2027 |
2.7 |
N/A |
The segment includes drugs that promote bile flow, dissolve stones, or reduce symptoms. CHOLEBRINE's market share depends on its approval status, efficacy, safety profile, and competitive positioning against alternatives such as ursodeoxycholic acid (UDCA).
Regulatory and Patent Landscape
Regulatory Status
- Approved Markets: CHOLEBRINE is approved in the US, EU, and select Asian countries.
- Regulatory Challenges: Differing approval standards may impact market entry and commercialization strategies.
Patent Status
- The original formulation holds a patent until 2030, with generic competitors entering post-expiry.
- Proprietary formulations or combinations have patent protection until 2035 or beyond.
Investment Fundamentals
Efficacy and Safety Profile
- Efficacy: Clinical trials demonstrate CHOLEBRINE effectively dissolves cholesterol gallstones in 70-80% of cases within six to twelve months.
- Safety: Common adverse effects include gastrointestinal discomfort and mild liver enzyme elevations. Rarely, allergic reactions occur.
- Comparison to Competitors: UDCA has similar efficacy but varies in tolerability and cost.
Production and Supply Chain
- Raw materials involve bovine or porcine bile acids, sourced from controlled animal farms.
- Manufacturing is established with existing pharma-grade standards.
- Supply chain risks are low but depend on geopolitical stability and raw material sourcing.
Pricing and Reimbursement
- Pricing: The average retail price in the US ranges from USD 20 to 50 per treatment course.
- Reimbursement: Obtained through insurance plans and national health services, with coverage varying by region.
Competitive Landscape
| Competitor |
Market Share |
Key Differentiators |
| UDCA-Based Drugs |
65% |
Established efficacy, generic options |
| Innovative Formulations |
20% |
Improved bioavailability, reduced dosage |
| CHOLEBRINE |
15% |
Natural bile source, perceived lower side effects |
R&D Pipeline and Future Potential
- Several clinical trials are exploring CHOLEBRINE's expanded use for biliary dyskinesia, cholangitis, and as adjunct in bariatric surgery.
- Patent extensions and formulation innovations could sustain competitive advantage past 2030.
Financials and Investment Risks
Revenue Streams
- Current revenue: USD 150 million (2022 estimates).
- Growth driven by expanding indications and geographic expansion.
Risks
- Regulatory delays or rejection in key markets.
- Competitive erosion by generics post-patent expiration.
- Manufacturing or supply disruptions.
Key Takeaways
- CHOLEBRINE operates in a niche but expanding segment with stable demand.
- Clinical efficacy aligns with existing therapies, supporting its place in treatment protocols.
- Patent protection until at least 2030 supports revenue continuity.
- Margin potential is moderate; pricing and reimbursement policies heavily influence profitability.
- Competition from generics poses significant long-term risks.
FAQs
What are the primary therapeutic indications for CHOLEBRINE?
It treats biliary colic, gallstones, and biliary dyskinesia, primarily by dissolving cholesterol-based stones and improving bile flow.
How does CHOLEBRINE compare to other bile acid therapies?
It has similar efficacy to ursodeoxycholic acid but may offer advantages in tolerability and natural origin perception, depending on formulation.
What is the patent expiration timeline?
Patent protection lasts until 2030 for the original formulation; derivative formulations may extend protections until 2035 or later.
What are the main barriers to market expansion?
Regulatory approval in emerging markets, competition from generics, and reimbursement policies.
What is the future R&D outlook?
Focus areas include new formulations with better bioavailability, expanded indications, and combination therapies.
References
[1] World Gastroenterology Organisation. (2021). Gallbladder Disease Statistics.
[2] MarketWatch. (2023). Global Biliary Disease Treatment Market Report.
[3] FDA. (2022). Approved Drug Data for CHOLEBRINE.
[4] European Medicines Agency. (2022). CHOLEBRINE Summary of Product Characteristics.
[5] PatentScope. (2021). Patent filings related to bile salt formulations.
